Expand DMAC Menu
DMAC MENU

DMAC Latest Press Releases

-- September 30, 2026 --

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results Business Wire 8:30 AM

-- September 2, 2026 --

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences Business Wire 8:30 AM

-- August 10, 2026 --

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Business Wire 4:30 PM

-- August 4, 2026 --

DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 Business Wire 4:30 PM

-- July 17, 2026 --

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- June 23, 2026 --

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction Business Wire 8:30 AM

-- June 16, 2026 --

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program Business Wire 8:30 AM

-- May 27, 2026 --

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 Business Wire 4:30 PM

-- May 20, 2026 --

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial Business Wire 8:30 AM

-- May 12, 2026 --

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference Business Wire 4:15 PM

-- May 6, 2026 --

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights Business Wire 4:30 PM
Market Data Delayed 15 Minutes